Browsing Department of Biomedicine by Subject "Targeted therapies"
Now showing items 1-1 of 1
-
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
(Peer reviewed; Journal article, 2019-08-15)Background Resistance to temozolomide (TMZ) is due in part to enhanced DNA repair mediated by high expression of O6-methyl guanine DNA methyltransferase (MGMT) that is often characterised by unmethylated promoter. Here, ...